

**INFORMED CONSENT
INFORMATION ABOUT DALBAVANCIN**

R12-0132
Cetero Research C12-0069

DUR001-104
Durata Therapeutics, Inc.

**A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND
PHARMACOKINETICS OF MULTIPLE WEEKLY DOSES OF INTRAVENOUS
DALBAVANCIN IN HEALTHY SUBJECTS**

I have volunteered to participate in this research study which will evaluate how the body processes the study drug, dalbavancin, when it is administered as weekly intravenous (IV) infusions (the medication is given through a vein in the arm) to healthy subjects. I understand the Durata Therapeutics, Inc. dalbavancin has not been approved by the Food and Drug Administration (FDA). Furthermore, I realize the following explanations are provided for my benefit and I must clearly understand the following information before signing my name to each page.

PRACS Institute Ltd.

RB Approved

03 Date 2-1-12

**THE DRUG BEING STUDIED IS A NEW, EXPERIMENTAL DRUG THAT HAS NOT
BEEN APPROVED BY THE UNITED STATES FOOD AND DRUG
ADMINISTRATION (FDA), OR ANY OTHER HEALTH AUTHORITY IN ANY
COUNTRY IN THE WORLD. THEREFORE ALL POTENTIAL EFFECTS OF THE
DRUG ARE NOT KNOWN AT THIS TIME.**

Dalbavancin is Not Categorized for Pregnancy: The risk of taking this product in pregnant women has not been fully determined from either human studies or animal studies.

**I SHOULD AVOID BECOMING PREGNANT OVER THE COURSE OF THE STUDY.
BECOMING PREGNANT WHILE PARTICIPATING IN A STUDY WILL EXPOSE ME
TO A POTENTIAL LOSS OF THE PREGNANCY, OR OTHER UNKNOWN EFFECTS
ON AN UNBORN CHILD SUCH AS, BUT NOT LIMITED TO, BIRTH DEFECTS AND
PREMATURE DELIVERY.**

I. PURPOSE OF THE STUDY

Dalbavancin is an antibiotic that is being studied as a new treatment option for complicated skin and soft tissue infections. Treatment of some infections such as osteomyelitis, an infection of the bone, may require longer durations of therapy. The purpose of this study is to analyze how weekly intravenous (IV) infusions of dalbavancin are handled by the body when it is given to healthy subjects. This study will also evaluate the safety and tolerability of weekly IV infusions of dalbavancin for up to 8 weeks.

II. PROCEDURES TO BE USED

A. Overview --

There will be 3 cohorts (groups) in this study, with 6 subjects participating in each cohort. Depending on my dosing cohort, I will receive 4, 6, or 8 weekly doses of

**INFORMED CONSENT
INFORMATION ABOUT DALBAVANCIN**

R12-0132
Cetero Research C12-0069

DUR001-104
Durata Therapeutics, Inc.

dalbavancin. All cohorts will receive a 1000 mg IV infusion of dalbavancin for the first dose and a 500 mg IV infusion of dalbavancin for all remaining doses.

Upon completing the study, I will have taken a dalbavancin product 4, 6, or 8 times (depending on my dosing cohort). There will be 18 volunteers (men and women) participating in the study and it will be done only at Cetero Research.

B. Duration –

This study consists of 2 confined dosing periods of at least 32 hours (first and last dose) and 2, 4, or 6 additional confined dosing periods (depending on my dosing cohort) of at least 21 hours. Each dose will be separated by at least a 7 day rest. The study also requires a pre-study screening and a post-study evaluation. Therefore, all study-related activities may occur over a 15 week period.

C. Screening Visit –

A staff member will explain all of the study procedures to me and will answer any questions or concerns I may have regarding the study. A staff member will ask me medical questions to determine whether I meet the requirements to participate in this study.

I will have a medication and medical history taken (I will inform the physician of any current or past medical problems). I will complete a physical examination which will include height and weight measurements, routine blood and urine tests, an electrocardiogram (a recording of the electrical activity of the heart), blood pressure, heart rate, breathing rate, and temperature evaluations, and screens for **drugs of abuse, tobacco use, pregnancy (females only), FSH (if necessary to document postmenopausal status), hepatitis B, hepatitis C, and AIDS (HIV testing)** before being accepted for this study.

D. Treatment Periods –

Day -1 (All Cohorts), 21 (Cohort I), 35 (Cohort II), and 49 (Cohort III)

I will report to the research unit by approximately 9:00 AM and will be confined to the research unit until after the 12 hour blood sample collection the next day.

At check-in and at any time during my stay at the research unit **my personal belongings may be searched for contraband** (such as food, beverages, chewing gum, candy, medications, strong smelling substances, or any item considered a weapon). Contraband is not allowed inside the research unit. Also, during my stay at the research unit, I will not be allowed to have visitors. All meals during my stay will be provided by the research unit and I will eat only the food provided at the scheduled meal times. **At each check-in, a urine sample will be collected for a drug abuse screen (all subjects) and blood samples will be collected for**

INFORMED CONSENT
INFORMATION ABOUT DALBAVANCIN

R12-0132
Cetero Research C12-0069

DUR001-104
Durata Therapeutics, Inc.

safety clinical laboratory tests (all subjects) and a pregnancy screen (females only).

Day 1 (All Cohorts), 22 (Cohort I), 36 (Cohort II), and 50 (Cohort III)

If dosing is scheduled for 8:00 AM, the following schedule will apply. **This is an example only.** The schedule of events will be dependent on dosing time. For example: I will be awakened by 6:45 AM in preparation for medication dosing at 8:00 AM.

A single dose of study drug will be given through a catheter (a small plastic tube that will be placed into a vein in my arm the evening prior to dosing). The IV catheter will be checked prior to dosing and may be changed if necessary. After fasting overnight, the study drug will be given over approximately 30 minutes. I will remain in bed during all dosing related procedures.

Blood samples will be collected within 60 minutes prior to the start of infusion (0-hour), at the end of infusion (approximately 0.5 hour), and at 1, 2, 3, 4, 6, 8, 10, and 12 hours after the start of infusion.

On Day 1, blood sample will be collected for safety clinical laboratory tests at approximately 12 hours after the start of infusion. Results will be reviewed by the investigator prior to release from the study site.

I will have my blood pressure, heart rate, breathing rate, and temperature checked prior to the start of infusion and prior to release from the research unit. Additional measurements may be obtained.

I will be able to leave the research unit after the 12 hour blood sample collection.

Days 7 and 14 (All Cohorts), 21 and 28 (Cohorts II and III), and 35 and 42 (Cohort III)

I will report to the research unit by approximately 9:00 AM and will be confined to the research unit until after the completion of study related procedures (approximately 1 hour after dosing) the next day.

At check-in and at any time during my stay at the research unit **my personal belongings may be searched for contraband** (such as food, beverages, chewing gum, candy, medications, strong smelling substances, or any item considered a weapon). Contraband is not allowed inside the research unit. Also, during my stay at the research unit, I will not be allowed to have visitors. **At each check-in, a blood sample will be collected for a pregnancy screen (females only).** If deemed necessary by the investigator, a urine sample will be collected for a drug abuse screen. **On Days 7 and 14 (all cohorts), 21 (Cohorts II and III),**

**INFORMED CONSENT
INFORMATION ABOUT DALBAVANCIN**

R12-0132
Cetero Research C12-0069

DUR001-104
Durata Therapeutics, Inc.

and 35 (Cohort III), blood samples will be collected for safety clinical laboratory tests (all subjects).

Days 8 and 15 (All Cohorts), 22 and 29 (Cohorts II and III), and 36 and 43 (Cohort III)

I will be awakened by 6:45 AM in preparation for medication dosing at 8:00 AM.

A single dose of study drug will be given through a catheter (placed the evening prior to dosing). The IV catheter will be checked prior to dosing and may be changed if necessary. After fasting overnight, the study drug will be given over approximately 30 minutes. I will remain in bed during all dosing related procedures.

Blood samples will be collected within 60 minutes prior to the start of infusion (0-hour) and at the end of infusion (approximately 0.5 hour).

I will have my blood pressure, heart rate, breathing rate, and temperature checked prior to the start of infusion and prior to release from the research unit. Additional measurements may be obtained.

I will be able to leave the research unit after completing all study related procedures.

Follow-up Visits: Days 29 and 36 (Cohort I), 43 and 50 (Cohorts I and II), 57 and 64 (Cohorts II and III), and 71 and 78 (Cohort III)

I will be required to return to the research unit for 4 follow-up visits (the visit days are based on my dosing cohort). I will have my blood pressure, heart rate, respiratory rate, and temperature measured and a blood sample for drug analysis will be collected. Additionally, at the last follow-up visit a physical examination and a pregnancy screen (females only) will be performed.

Any out of range clinical laboratory tests or ongoing adverse events will be followed until resolution.

E. Over the Course of the Study –

During the study, I will be periodically asked how I am feeling.

Blood samples will be collected by direct blood draw for laboratory screening, pregnancy screens (females only), and drug sample collections:

- For male subjects, blood samples will be collected up to a maximum of 42 times

**INFORMED CONSENT
INFORMATION ABOUT DALBAVANCIN**

R12-0132
Cetero Research C12-0069

DUR001-104
Durata Therapeutics, Inc.

- For female subjects, blood samples will be collected up to a maximum of 45 times

The total amount of blood drawn should not exceed 500 mL or 1.4 cans of soda pop.

F. Requirements for participation –

I understand I must be 18 to 55 years of age, inclusive.

If female, participants must be either:

- naturally postmenopausal (no menses) for at least 1 year and if younger than 55 years of age has a documented FSH level to support postmenopausal status;
or
- surgically postmenopausal (bilateral oophorectomy [both ovaries removed] or hysterectomy [uterus removed]); **or**

Female volunteers that are surgically postmenopausal must provide documentation of the bilateral oophorectomy or hysterectomy prior to Day 1 dosing or must agree to use a medically acceptable non-hormonal method of birth control.

- surgically sterile (bilateral tubal ligation [tubes tied]) or the Essure procedure;
or

Female volunteers that are surgically sterile must provide documentation of the bilateral tubal ligation prior to Day 1 dosing or must agree to use a medically acceptable non-hormonal method of birth control. The Essure Procedure must have been inserted at least 3 months with documentation of the Essure confirmation test provided prior to Day 1 dosing. If the procedure was inserted less than 3 months prior to Day 1 dosing or proper documentation is not provided, the subject must agree to use an additional non-hormonal medically acceptable method of birth control.

- practicing a medically acceptable method of birth control.

Female volunteers of childbearing potential must be practicing and agree to utilize one of the following non-hormonal methods (from the screening visit until study completion) or hormonal methods of contraception throughout the study:

Non-Hormonal Birth Control

- condom and spermicide (foam, cream, gel, sponge)
- condom and diaphragm
- diaphragm and spermicide (foam, cream, gel)

INFORMED CONSENT
INFORMATION ABOUT DALBAVANCIN

R12-0132
Cetero Research C12-0069

DUR001-104
Durata Therapeutics, Inc.

- non-hormonal intrauterine device (IUD)
- complete abstinence

If abstinence is my chosen method of birth control, I agree not to have sex over the course of the study.

Hormonal Birth Control

- Oral contraceptives (birth control pills [eg, Yasmin, Alesse, Ortho Tri-Cyclen]), contraceptive vaginal ring (eg, NuvaRing) or insert, or a contraceptive patch (eg, Ortho Evra) must be used for at least 3 consecutive months prior to Day 1 dosing and throughout the study. If I have discontinued use of an oral (birth control pills), ring, insert, or patch birth control method I must not have taken any for at least 28 consecutive days prior to Day 1 dosing to be eligible for study participation.
- Injectable contraceptive (eg, Depo-Provera) must be used for at least 6 consecutive months prior to Day 1 dosing and throughout the study. If I have discontinued the use of an injectable contraceptive, I must not have received my last injection within the last 12 consecutive months prior to Day 1 dosing to be eligible for study participation. Documentation of my last dose will be required to be eligible for study participation.
- Contraceptive intrauterine device (IUD [eg, Mirena]) or contraceptive implant (eg, Implanon) must be used for at least 6 consecutive months prior to Day 1 dosing and throughout the study. If I have discontinued the use of a hormonal IUD or contraceptive implant, I must have had the device removed for at least 12 consecutive months prior to Day 1 dosing to be eligible for study participation. Documentation of the insertion and/or removal will be required to be eligible for study participation.

If I am a male, I understand that I must use a condom and, if I have not also had a vasectomy, I must use another form of contraception, such as an IUD, spermicidal foam/gel/ film/cream/suppository, diaphragm with spermicide, oral contraceptive, injectable progesterone, or subdermal implant, to prevent the pregnancy of my female partner, if she could still become pregnant, from the time of the first dose of study medication until after last study visit.

I have been informed I cannot enter this study if I have a history or evidence of serious medical problems involving the kidneys, digestive system, heart and blood vessels, lungs, liver, eyes, nerves, brain, skin, thyroid, bones or blood; or such diseases as glaucoma, epilepsy, psychosis, mental illness such as a personal history of depression, diabetes, cancer, tuberculosis, asthma, a blood disease or autoimmune problems. I will also be excluded if I have a history of alcoholism or

INFORMED CONSENT
INFORMATION ABOUT DALBAVANCIN

R12-0132
Cetero Research C12-0069

DUR001-104
Durata Therapeutics, Inc.

drug abuse within the past year; use or have used tobacco or nicotine products within the past 6 months; or have a significant history of allergies; or allergies to or adverse experiences with dalbavancin, glycopeptides (e.g. vancomycin), or other related medications.

I have been informed I must comply with the following:

1. **No investigational drug** within **28 days** prior to Day 1 dosing and throughout the study.
2. **No prescription medications or drugs** should be taken for **14 days** prior to Day 1 dosing and throughout the study, with the exception of hormonal contraceptives (eg, birth control pills) for female volunteers.
3. **No over-the-counter medications or drugs** including aspirin, ibuprofen, naproxen or acetaminophen should be taken for **3 days** prior to Day 1 dosing and throughout the study, with the exception of spermicide.
4. **No drug or substance known to inhibit CYP enzymes** (quinidine [Quinidex], ketoconazole [Nizoral], fluconazole [Diflucan], cimetidine [Tagamet]) within **14 days** prior to Day 1 dosing and throughout the study.
5. **No drug or substance known to induce CYP enzymes** (rifampin [Rifadin], phenytoin [Dilantin], carbamazepine [Tegretol], omeprazole [Prilosec]) within **28 days** prior to Day 1 dosing and throughout the study.
6. **No hormone replacement therapy (HRT)** should be taken for **6 months** prior to Day 1 dosing and throughout the study.
7. **No herbal or dietary supplements** should be taken for **3 days** prior to Day 1 dosing and throughout the study.
8. **No therapeutic dose of any vitamins** should be taken for **3 days** prior to Day 1 dosing and throughout the study.
9. Standard daily dose multivitamins (non-therapeutic doses) may be consumed until initial check-in and will be restricted until the end of the study.
10. Vitamin waters may be consumed until initial check-in and will be restricted until the end of the study.
11. **No St. John's Wort** should be taken for **28 days** prior to Day 1 dosing and **through 14 days** after the last dose administration.

**INFORMED CONSENT
INFORMATION ABOUT DALBAVANCIN**

R12-0132
Cetero Research C12-0069

DUR001-104
Durata Therapeutics, Inc.

-
12. **No medication will be allowed during the study** without first obtaining the approval of the investigator(s).
 13. **No caffeine or xanthine such as coffee, tea, chocolate, and all caffeine- or xanthine-containing soft drinks or energy drinks** should be consumed for **48 hours** prior to each dose and during the periods when blood samples are collected.
 14. **No beverages containing more than 5% juice** should be consumed for **48 hours** prior to each dose and during the periods when blood samples are collected.
 15. **No grapefruit, Seville oranges, and pomelo-containing products** should be consumed for **14 days** prior to Day 1 dosing and throughout the study until the last blood samples are collected.
 16. **No alcoholic beverages and/or other alcohol-containing products** should be consumed for **48 hours** prior to each dose and during the periods when blood samples are collected.
 17. **No food products containing poppy seeds** should be consumed for **48 hours** prior to each dose and during the periods when blood samples are collected.
 18. **I should not participate if I have donated blood** within **28 days** prior to Day 1 dosing and I should not donate blood until 4 weeks after completing the study.
 19. **I should not participate if I have donated plasma** (via plasmapheresis) within **14 days** prior to Day 1 dosing and I should not donate plasma until 4 weeks after completing the study.
 20. **I should not participate if I have a history of fainting, collapse, syncope** (loss of consciousness), **orthostatic hypotension** (low blood pressure upon standing), **or vasovagal reactions** (brief loss of consciousness caused by a sudden drop in heart rate and blood pressure).
 21. **I should not participate if I have an intolerance of direct venipuncture or if I have veins unsuitable for IV puncture on either arm** (ie, difficult to locate, access, or puncture, or veins with a tendency to rupture during or after puncture).
 22. **I should not participate if I have difficulty fasting or consuming a standard meal.**

**INFORMED CONSENT
INFORMATION ABOUT DALBAVANCIN**

R12-0132
Cetero Research C12-0069

DUR001-104
Durata Therapeutics, Inc.

23. I will not be allowed to participate if I test positive for drugs of abuse, alcohol, or tobacco use.
24. I will not be allowed to participate if I have a clinically significant illness within 28 days prior to Day 1 dosing as determined by the investigator(s).
25. I will not be allowed to participate if I have any clinically significant results from laboratory tests, vital sign measurements, and electrocardiograms, as determined by the investigator(s).
26. I will not be allowed to participate for any reason which, in the opinion of the investigator(s), would prevent me from safely participating in the study.
27. I should not participate if I am pregnant, lactating, breastfeeding, or intend to become pregnant over the course of the study (females only).
28. My medication history over the past month will be reviewed and I may not participate if any of the medications may change how drugs are absorbed or eliminated.

III. INCONVENIENCES AND POSSIBLE ADVERSE EVENTS

A. Inconveniences –

I will not be allowed to consume Vitamin waters from the time of initial check-in until the end of the study.

I will not be allowed to consume the following products 48 hours prior to each dose and during the periods when blood samples are collected:

- caffeine or xanthine products such as coffee, tea, chocolate, soft drinks, or energy drinks
- beverages containing more than 5% fruit juice (fruit drinks, fruit punches, fruit cocktails, etc. containing less than or equal to 5% fruit juice are allowed)
- alcoholic beverages and/or other alcohol-containing products
- food products containing poppy seeds

I will not be allowed to consume grapefruit, Seville oranges, and pomelo-containing products 14 days prior to Day 1 dosing and throughout the study until the last blood samples are collected.

I will be confined to the research unit for 2 dosing periods of at least 32 hours (first and last dose) and either 2, 4, or 6 additional dosing periods (depending on

**INFORMED CONSENT
INFORMATION ABOUT DALBAVANCIN**

R12-0132
Cetero Research C12-0069

DUR001-104
Durata Therapeutics, Inc.

my dosing cohort) of at least 21 hours. I will not be allowed to have visitors during the confinement periods. **I will be required to return to the research unit for 4 follow-up visits. These visits will occur on Days 29 and 36 (Cohort I), 43 and 50 (Cohorts I and II), 57 and 64 (Cohorts II and III), and 71 and 78 (Cohort III).**

Reminder: Times listed in this consent are examples only. I will be informed of actual times through a check-in reminder phone call and by study staff once enrolled in the study.

B. Possible Adverse Events -

1. Local pain, bruising, bleeding, and inflammation or infection might occur at the site of the needle stick where blood is drawn. There is also the possibility of dizziness or fainting while my blood is being drawn. Precautions will be taken to minimize these difficulties.
2. The place(s) on my arm where the catheter is placed and the venous infusion is given, may bruise or feel tender or uncomfortable for 2-3 days after the infusion. If bleeding occurs, I should apply pressure to the place on my arm and notify the study staff immediately. Redness, pain, or swelling at the infusion site may occur. If these symptoms worsen, notify the study staff immediately.
3. Adverse events (side effects) are possible with any drug and I might experience some adverse events during this study. In previous studies in which patients received two doses of dalbavancin rather than the four to eight doses being given in this study, adverse events, mostly of mild or moderate severity, have been associated with the use of dalbavancin. Events seen in 2% or more of patients have included (but may not be limited to) the following:
 - anemia (low red blood count)
 - constipation
 - diarrhea
 - fever
 - headache
 - insomnia (inability to sleep)
 - nausea
 - pruritus (severe itching)
 - rash
 - urinary tract infection
 - vomiting

**INFORMED CONSENT
INFORMATION ABOUT DALBAVANCIN**

R12-0132
Cetero Research C12-0069

DUR001-104
Durata Therapeutics, Inc.

4. Females: There is a slight risk that a pregnancy test could be falsely negative, thus exposing me to a potential loss of pregnancy as well as other unknown effects on a fetus such as but not limited to birth defects and premature delivery. I will be withdrawn from the study participation if I become pregnant or have a positive pregnancy screen. My doctor may also want to continue to be in contact with me if I become pregnant and carry the baby to delivery.
5. I will be informed if any new risks become known during the course of this study. For my own protection, I agree to report any adverse effect I have to Dr. Sprenger, Dr. Copa, or Dr. Godfrey. If I have an adverse effect, Drs. Sprenger/Copa/Godfrey may, for my protection, stop my participation in the study.

IV. BENEFITS

I will receive no medical benefit from participation in this study other than the routine medical and laboratory examination results of my pre-study screening and exit evaluations, if I so request. However, the knowledge gained by this study may contribute to information which would allow the use of the drug in future patient treatment.

If I participate in Cohort I, I will receive \$1,700 for successfully completing the study as previously outlined. If I do not complete the study as described, I will be paid on a prorated basis.

If I participate in Cohort II, I will receive \$1,900 for successfully completing the study as previously outlined. If I do not complete the study as described, I will be paid on a prorated basis.

If I participate in Cohort III, I will receive \$2,100 for successfully completing the study as previously outlined. If I do not complete the study as described, I will be paid on a prorated basis.

V. ALTERNATIVE TREATMENTS

This research study is not for treatment of a medical condition and therefore the only alternative is to not participate.

VI. COMPENSATION AND TREATMENT FOR INJURY

In the unlikely event I sustain a physical injury because of my participation in this study as a direct result of the administration of the drugs or in the drawing of blood samples or other tests, immediate first aid will be supplied to me. All reasonable medical expenses not covered by my personal medical insurance will be paid by Durata Therapeutics, Inc. or Cetero Research provided the expenses are, in fact, due to injury resulting from the

**INFORMED CONSENT
INFORMATION ABOUT DALBAVANCIN**

R12-0132
Cetero Research C12-0069

DUR001-104
Durata Therapeutics, Inc.

investigational study, I have followed the investigational study requirements and I have immediately notified the investigator(s) of the injury. I also understand no financial compensation other than the treatment listed above is available from Durata Therapeutics, Inc. or Cetero Research. I further understand I do not give up any of my legal rights by signing this form. Should I require further information concerning compensation and treatment for injury, I should contact the investigator(s), Craig R. Sprenger, MD at (701) 239-4750, Alan K. Copa, PharmD at (701) 239-4750 or (701) 371-6735, or Anthony R. Godfrey, PharmD at (701) 239-4750 or (701) 866-3022.

VII. QUESTIONS ABOUT THE STUDY

I have the right to ask Cetero Research staff or Craig R. Sprenger, MD at (701) 239-4750, Alan K. Copa, PharmD at (701) 239-4750 or (701) 371-6735, or Anthony R. Godfrey, PharmD at (701) 239-4750 or (701) 866-3022 any questions about my rights as a study participant or any questions concerning the potential or known hazards of this study at any time without prejudice. I also have the right to withdraw from the study at any time without prejudice. If I withdraw from the study, I understand that any samples or data collected prior to my withdrawal may be utilized and/or analyzed, unless I provide written withdrawal of my consent. If I should decide to withdraw after receiving study medication, I will be encouraged to have a post-study evaluation. This evaluation is to detect any unexpected adverse events. I should also understand participation or the refusal to participate in the study will in no way influence my medical care by the investigator(s) or other medical personnel. I understand my participation in this study may be terminated at any time when in the judgment of the investigator(s), Drs. Sprenger//Copa/Godfrey it is in my best interest.

I may also contact William Henderson, PhD, Institutional Review Board member, at (701) 239-4750. The Institutional Review Board is an independent ethics committee that reviews the studies conducted at Cetero Research and protects the rights of the subjects.

VIII. CONFIDENTIALITY

The medical information gathered from this study will be submitted to the appropriate representatives of Durata Therapeutics, Inc. and the Food and Drug Administration of the United States Government under the regulations issued by the federal agency and to other regulatory agencies. Representatives from the U.S. Food and Drug Administration and Durata Therapeutics, Inc. may review my medical records to ensure the accuracy of the information submitted by the investigators.

The collection and submission of the medical information from this study to the appropriate representatives of Durata Therapeutics, Inc. and the U.S. Food and Drug Administration will be accomplished with strict adherence to professional standards of confidentiality. My name and address will be filed under adequate security for use in case future follow-up becomes necessary.

**INFORMED CONSENT
INFORMATION ABOUT DALBAVANCIN**

R12-0132
Cetero Research C12-0069

DUR001-104
Durata Therapeutics, Inc.

IX. HIPAA AUTHORIZATION TO USE AND DISCLOSE PERSONAL HEALTH INFORMATION

A federal regulation known as the Privacy Rule gives me certain rights concerning the privacy of my health information. The Privacy Rule was issued under a law called the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Researchers covered by this regulation are required to get my authorization (permission) to use and disclose (share with others) any health information that could identify me.

If I sign this informed consent form, I am giving permission for the use and disclosure of my health information for purposes of this research study. I do not have to give this permission. However, if I do not, I will not be able to participate in the study.

A. Who Will Use and Disclose My Health Information?

The investigator and the Study Team (research staff) at Cetero Research may use my health information to conduct, review, and determine the results of the study. The Study Team may also use my information to prepare reports or publications about the study. However, my name will not appear in any report or publication. The Study Team may disclose my information to others, as discussed below.

B. What Health Information Will be Used and Disclosed?

The Study Team will record my medical history, the treatment I receive, and the results of examinations and tests done during the study on study forms. My name will not appear on the study forms. Instead, I will be assigned a subject identification number. The Study Team will send the completed study forms to the study sponsor. This type of information may also be shared with others, as described below.

My medical records may include other health information about me and may include documents that directly identify me. Representatives from the groups identified below may need to look at my medical records to make sure that the information on the study forms are correct or that the study was conducted properly. Reviews like that will take place at the study center or where the medical records are stored and can take place after the study is over.

C. Who Will Receive My Health Information?

My study information may be shared with the following people or groups:

- The study sponsor or its representatives, including companies it hires to provide study-related services
- Researchers who are conducting this study at other study centers.
- The Institutional Review Board (ethics committee) that approved this study and any other committees responsible for overseeing the research.

**INFORMED CONSENT
INFORMATION ABOUT DALBAVANCIN**

R12-0132
Cetero Research C12-0069

DUR001-104
Durata Therapeutics, Inc.

- Government health agencies (such as the Food and Drug Administration) in the US or other countries.

Representatives from these groups may receive information from my study forms or may review my medical records (as described above) or both.

D. Will My Information Be Protected by the Privacy Rule After It Is Disclosed to Others?

Cetero Research is required by the Privacy Rule to protect my health information. After my information is shared with others, like the study sponsor, it may no longer be protected by the Privacy Rule. The people who receive this information could use it in ways not discussed in this form and could disclose it to others. The sponsor will use and disclose my information only for research or regulatory purposes or to prepare research publications. In addition to using it for this study, the sponsor may reanalyze the study data at a later date or combine my information with information from other studies for research purposes not directly related to this study. The goal of any such research would be to learn more about drugs or diseases or to help design better studies in the future. When using the information in these ways, the sponsor may share it with regulatory authorities, other researchers, its business partners, or companies it hires to provide research-related services. However, my name will never appear in any sponsor forms, reports, databases, or publications, or in any future disclosures by the sponsor.

E. What Happens If I Leave the Study Early?

If I stop participating in the study early for any reason, the Study Team will tell the sponsor why. If the Study Team asks me to come to any more study visits and I agree, the Study Team will send the sponsor information from those visits as well. All information collected about me may continue to be used and disclosed.

F. Will My Authorization Ever Expire?

This Authorization does not have an expiration date. The Study Team may need to correct or provide missing information about me even after my study participation is over. The review of my medical records (described above) may also take place after the study is over.

G. May I Take Back My Authorization?

I have the right to take back (revoke) my Authorization at any time by writing to Craig R. Sprenger, MD, Alan K. Copa, PharmD, or Anthony R. Godfrey, PharmD at Cetero Research, 4801 Amber Valley Parkway, Fargo, ND 58104. If I revoke my Authorization, the Study Team will not collect any new health information about me. However, they can continue to use and disclose any already collected information if that is necessary for the reliability of the study. The sponsor can

**INFORMED CONSENT
INFORMATION ABOUT DALBAVANCIN**

R12-0132
Cetero Research C12-0069

DUR001-104
Durata Therapeutics, Inc.

also still keep and use any information that it has already received. If I revoke my Authorization, I can no longer continue to participate in the study.

H. May I Look at My Study Information?

I have a right to see and make copies of my medical records. However, to ensure the reliability of the study, I will need to wait to see my study records until the study is completed.

